GlassScriptPhysician profile
Jason P Caplan
NPI 1538196456
$998,640.09
in general payments reported to CMS, 2019-2025
9 companies · $118K in 2025
The $118K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326K · 2020: $121K · 2021: $100K · 2022: $106K · 2023: $104K · 2024: $123K · 2025: $118K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $255K · Consulting Fee: $46K · Travel and Lodging: $38K · Food and Beverage: $7,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $254,812.50 |
| Consulting Fee | $45,871.50 |
| Travel and Lodging | $37,793.94 |
| Food and Beverage | $7,375.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $396,268.10 | 2019-2025 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $238,159.26 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $183,896.01 | 2019-2023 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $112,483.74 | 2023-2025 | Nuedexta, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $53,461.85 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $5,400.00 | 2019 | |
| Sage Therapeutics, LLC | $5,040.00 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,825.29 | 2019-2024 | Rexulti |
| Bioxcel Therapeutics, INC. | $105.84 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Caplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.